MA55752A - Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies - Google Patents

Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies

Info

Publication number
MA55752A
MA55752A MA055752A MA55752A MA55752A MA 55752 A MA55752 A MA 55752A MA 055752 A MA055752 A MA 055752A MA 55752 A MA55752 A MA 55752A MA 55752 A MA55752 A MA 55752A
Authority
MA
Morocco
Prior art keywords
nephropathies
treatment
pharmaceutical compositions
new compounds
associated pharmaceutical
Prior art date
Application number
MA055752A
Other languages
English (en)
Inventor
Reginald Christophe Xavier Brys
Thierry Jean-Claude Marie Christophe
Katja Els Conrath
Der Geest Ronald Van
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MA55752A publication Critical patent/MA55752A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055752A 2019-04-24 2020-04-21 Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies MA55752A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1905711.6A GB201905711D0 (en) 2019-04-24 2019-04-24 Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases

Publications (1)

Publication Number Publication Date
MA55752A true MA55752A (fr) 2022-03-02

Family

ID=66810218

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055752A MA55752A (fr) 2019-04-24 2020-04-21 Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies

Country Status (15)

Country Link
US (1) US20220202802A1 (fr)
EP (1) EP3958863B1 (fr)
JP (1) JP7543304B2 (fr)
KR (1) KR20220004111A (fr)
CN (1) CN113727711A (fr)
AU (1) AU2020263869A1 (fr)
BR (1) BR112021021117A2 (fr)
CA (1) CA3137445A1 (fr)
ES (1) ES2982398T3 (fr)
GB (1) GB201905711D0 (fr)
IL (1) IL287392A (fr)
MA (1) MA55752A (fr)
MX (1) MX2021012544A (fr)
SG (1) SG11202111739VA (fr)
WO (1) WO2020216740A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362031B2 (en) 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
WO2011019737A1 (fr) * 2009-08-10 2011-02-17 The Regents Of The University Of California Inhibiteurs pyrimido-pyrrolo-quinoxaline dione de la protéine régulatrice de la conductance transmembranaire impliquée dans la fibrose kystique et leurs utilisations
TWI633887B (zh) * 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
WO2016073470A1 (fr) * 2014-11-04 2016-05-12 The University Of Kansas Activateurs de l'ampk de lkb1 pour une utilisation thérapeutique dans la polykystose rénale
US9890158B2 (en) * 2015-10-09 2018-02-13 Abbvie S.Á.R.L. N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
EP3359540A1 (fr) 2015-10-09 2018-08-15 AbbVie S.À.R.L. Nouveaux composés destinés au traitement de la fibrose kystique
CA3001094A1 (fr) 2015-10-09 2017-04-13 Abbvie S.A.R.L. Acides pyrazolo[3,4-b]pyridin-6-carboxyliques substitues et leur utilisation
WO2018237174A2 (fr) * 2017-06-21 2018-12-27 The Johns Hopkins University Modulateurs de régulateur de conductance transmembranaire de fibrose kystique pour le traitement d'une polykystose rénale autosomique dominante

Also Published As

Publication number Publication date
ES2982398T3 (es) 2024-10-16
CN113727711A (zh) 2021-11-30
EP3958863A1 (fr) 2022-03-02
WO2020216740A1 (fr) 2020-10-29
JP2022529814A (ja) 2022-06-24
KR20220004111A (ko) 2022-01-11
US20220202802A1 (en) 2022-06-30
BR112021021117A2 (pt) 2021-12-14
AU2020263869A1 (en) 2021-12-23
GB201905711D0 (en) 2019-06-05
EP3958863C0 (fr) 2024-07-03
JP7543304B2 (ja) 2024-09-02
MX2021012544A (es) 2021-11-12
CA3137445A1 (fr) 2020-10-29
SG11202111739VA (en) 2021-11-29
EP3958863B1 (fr) 2024-07-03
IL287392A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA51739A (fr) Compositions pharmaceutiques pour le traitement de la fibrose kystique
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA52118A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA55974A (fr) Composés triaryles pour le traitement de maladies pd-l1
LU92577B1 (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose
MA55325A (fr) Composés pour le traitement de maladies pd-l1
LU92578B1 (fr) Nouveaux composés et compostions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA51916A (fr) Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide
MA55497A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires
MA56212A (fr) Compositions et méthodes de traitement du cancer
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
MA52219A (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
MA55143A (fr) Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
MA54792A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson